Brought to you by

Inverness Medical buys Cholestech for $299mm in stock
02 Jul 2007
Executive Summary
Inverness Medical Innovations will acquire fellow point-of-care diagnostics company Cholestech by providing shareholders with 0.44 shares of Inverness common stock for each Cholestech share they own or about $19.17 per share (a 12% premium), for a total of $299mm.
Deal Industry
- Biotechnology
- In Vitro Diagnostics
-
In Vitro Diagnostics
- Chemistry, Immunoassay
- Glucose Testing
- Therapeutic Drug Monitoring
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Payment Includes Stock
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com